Actinogen (ASX:ACW) has received positive initial results from its Cancer Stem Cell project with several isolates from its library demonstrating the ability to counteract the formation of tumours.
Researchers at Curtin University tested 11 isolates from the company’s library on their ability to demonstrate antitumorigenic effects by affecting the viability of cancer stem cells in selected glioblastoma cell lines.
Glioblastoma is considered as the most aggressive type of brain cancer.
Cancer cell populations were reduced by about 80% by two of the isolates, which are consistent with previous internal results and supports the strong anti-cancer activity of some of the actinomycetes isolates.
CSC sphere disruption, cell anchorage, and cell death were observed with different isolates for the CSCs across all 4 cell lines.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.